Pilot study investigating syndecan-1 and other endothelial damage markers in surgical patients

Pilot study investigating syndecan-1 and other endothelial damage markers in surgical patients - PEPC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038107

Enrollment

100

Registered

2025-10-27

Start date

2025-11-12

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative complications

Interventions

Group 1: Adult patients undergoing elective surgery, stratified in 4 groups: cardaic surgery, open surgery, laparoscopic surgery, and low-risk surgery. Endothelial biomarker panel at three different t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Elective cardiac surgery (25 patients) Open surgery (all disciplines) (25 patients) Laparoscopic surgery (all disciplines) (25 patients) and low-risk surgery (all disciplines) (25 patients) Informed consent (including broad consent for biobank).

Exclusion criteria

Exclusion criteria: Age <18 years. • Emergency procedures. • Incapacity to consent. • Pregnancy. • Operations <60 minutes. • Outpatient procedures. • Severe comorbidities (e.g., renal failure with GFR <30 mL/min/1.73 m², or liver failure with Child-Pugh C). • Medications that affect the endothelium (e.g., high-dose corticosteroids).

Design outcomes

Primary

Measure	Time frame
Difference in syndecan 1 plasma concentration (in ng/mL) between pre- and postoperative measurements as a marker for acute glycocalyx damage. Time points: Preoperative (day 0): baseline blood sampling (5 mL + 2 mL citrate plasma); Postoperative (<1h): blood sampling (5 mL + 2 mL) 24h postoperative: blood sampling (5 mL + 2 mL);	—

Secondary

Measure	Time frame
Concentrations of all markers (syndecan-1, heparan sulfate, hyaluronic acid, thrombomodulin, angiopoietin-2, MMP-2, MMP-9) at all three time points; postoperative organ function (SOFA score); complication rates; length of hospital stay; perioperative vital signs and laboratory values; exploratory analyses of correlations between biomarkers, clinical outcomes, and perioperative parameters. Time points: Preoperative (day 0): baseline blood sampling (5 mL + 2 mL citrate plasma); Postoperative (<1h): blood sampling (5 mL + 2 mL) 24h postoperative: blood sampling (5 mL + 2 mL);	—

Measure

Time frame

Concentrations of all markers (syndecan-1, heparan sulfate, hyaluronic acid, thrombomodulin, angiopoietin-2, MMP-2, MMP-9) at all three time points; postoperative organ function (SOFA score); complication rates; length of hospital stay; perioperative vital signs and laboratory values; exploratory analyses of correlations between biomarkers, clinical outcomes, and perioperative parameters. Time points: Preoperative (day 0): baseline blood sampling (5 mL + 2 mL citrate plasma); Postoperative (<1h): blood sampling (5 mL + 2 mL) 24h postoperative: blood sampling (5 mL + 2 mL);

—

Countries

Germany

Contacts

Public ContactMichael Nordine

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie (KAIS)

nordine@med.uni-frankfurt.de+49 069 6301 84199

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026